Immunotherapy Drugs Market Synopsis

Immunotherapy Drugs Market Size Was Valued at USD 125.5 Billion in 2023, and is Projected to Reach USD 224.9 Billion by 2032, Growing at a CAGR of 6.7% From 2024-2032.

The Immunotherapy drugs market relates to a niche in the pharma industry in which compounds are produced with the specific purpose of either boosting or suppressing the body’s immune system response to diseases. These drugs are used mainly as chemotherapeutic agents to cure cancer, autoimmune diseases, chronic conditions from enhancing the body’s immune system function. Immunotherapy is either consisting of drugs that enhance the activity of the immune system in attacking cancer cells or supplying the immune system with the necessary tools to do so. Market has also received a lot of attention due to Cancer care and other health improvements and necessities.

• The immunotherapy drugs market has also grown fast over the recent years because of the increased demand for drugs that address complex diseases such as cancer, autoimmune diseases and inflammatory diseases. With the advancement in medical sciences immunotherapy is the most sought after treatment modalities of the twenty first century which try to use body’s own immune system to fight ailments. Global market is driven by higher occurrences of cancer, growing autoimmune diseases and large-scale research and development of biological drugs. availability of such treatments within a region also boosts market expansion efforts and public and healthcare programs supporting such accesses are also other factors that are driving this market.
• Immunotherapy drugs are proving much more effective than chemotherapy or radiation hence multinational pharmaceutical manufacturing giants are betting big on new immunotherapy drugs. CAR-T cell therapy, checkpoint inhibitors, monoclonal antibodies and others have already rewritten the book on cancer treatment. Yet even today issues such as excessively high costs of the treatments, problems associated with legislation and still again – appropriateness of these drugs in the site of developing countries are still to be resolved. Thus, the market will grow further when there are new therapeutic categorized in immunotherapy and the focus on personalized medicine is further developed.

Immunotherapy Drugs Market Trend Analysis

Rising Focus on CAR-T Cell Therapy

• A very key feature of the immunotherapy drugs market is direction towards CAR-T cell therapy, the innovative treatment that means usage of modified cells to treat cancer. This therapy has proven incredibly effective for some forms of blood cancers, and is progressively being used across other forms of tumors. CAR-T therapies such as Kymriah and Yescarta are examples new industry defining treatments as these being specific healthcare products are personalized to the genetic make-up of each patient. The increase in the development of such therapies is also expected because the companies strive to improve the efficacy of the treatment, minimize the side effects of the treatment as well as try to make a CAR-T therapy available to more patients.

Expanding Applications in Autoimmune Diseases

• Other key opportunity of immunotherapy drugs is in auto-immune diseases where the drugs were not initially applied: rheumatoid arthritis, multiple sclerosis and lupus, for example. Currently, the biopharmaceutical firms are conducting various analyzes to find out how immunotherapies can work to control the immune system from attacking other healthy tissues. Also, therapies concerning discretional immune pathways provide the opportunities for targeting individual autoimmune diseases. Since autoimmune diseases are projected to contribute to a large burden in the future, especially in developed regions, the market in this area has tinted with golden opportunities for growth in the coming few years.

Immunotherapy Drugs Market Segment Analysis:

Immunotherapy Drugs Market Segmented on the basis of type and Indication.

By Type, Monoclonal antibodies segment is expected to dominate the market during the forecast period

• Biosimilars for monoclonal antibodies are anticipated to account for the most significant market share within immunotherapy drugs market during the forecast period due to strong recorded results in the treatment for various diseases such as cancer, auto immune and inflammation disorders. These are created to go for particular antigens bound on the exterior of injurious cells and are very effective in enhancing immune response. This has made them safer and more potent and hence widely used in the clinical practice today’s and advancement in the monoclonal antibody technology including the humanized as well as fully human antibodies. Many firms are looking forward to increase the applications of monoclonal antibodies for several therapeutic segments which will help in the growth of the segment.

By Indication, Cancer segment expected to held the largest share

• Immunotherapy drugs are used for various indications, of which cancer treatment is expected to dominate during the forecast period. Immunotherapy has washed through the oncology space and has completed new modes of treatment for individual who had not well responded to developmental therapies. Two novel drugs that assist the immune system in recognising and eliminating cancer cells, namely Keytruda and Opdivo have been approved and have brought great changes to cancer treatment and extended the functions of immunotherapy. However, it is expected that the upward growth of the cancer segment will continue as global research into solid tumors and combination therapy increases, and the global incidence of cancer rises, and the need for more effective treatment with fewer side effects grows.

Immunotherapy Drugs Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• According to the study, in 2023 the America regional claiming the most in the immunotherapy drugs tourist percentage was North America that was dominated by the US. The high dominance of the region is because of the highly developed companies manufacturing drugs, efficient and effective health systems, and a high number of patients suffering from chronic diseases, and especially cancer. According to the report, in 2023, North America would continue occupying approximately 40% of the global immunotherapy drugs market by revenue, benefited from large government support for cancer research, and friendly environment for fast track approvals of new drugs. Moreover, the continuously industrial growth in the North America where there is high demand for the personalized medicine and further research always being carried out on immunotherapies like CAR-T therapies has further cemented the leadership of this market.

Active Key Players in the Immunotherapy Drugs Market

• AbbVie Inc. (United States)
• Amgen Inc. (United States)
• AstraZeneca (United Kingdom)
• Bayer AG (Germany)
• Bristol-Myers Squibb (United States)
• Eli Lilly and Company (United States)
• Gilead Sciences (United States)
• GlaxoSmithKline (United Kingdom)
• Johnson & Johnson (United States)
• Merck & Co. (United States)
• Novartis AG (Switzerland)
• Pfizer Inc. (United States)
• Roche Holding AG (Switzerland)
• Sanofi (France)
• Takeda Pharmaceutical Company (Japan)
• Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Immunotherapy Drugs Market by Type
 4.1 Immunotherapy Drugs Market Snapshot and Growth Engine
 4.2 Immunotherapy Drugs Market Overview
 4.3 Monoclonal antibodies
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Monoclonal antibodies: Geographic Segmentation Analysis
 4.4 Immunomodulators
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Immunomodulators: Geographic Segmentation Analysis
 4.5 Vaccines
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Vaccines: Geographic Segmentation Analysis

Chapter 5: Immunotherapy Drugs Market by Indication
 5.1 Immunotherapy Drugs Market Snapshot and Growth Engine
 5.2 Immunotherapy Drugs Market Overview
 5.3 Cancer
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Cancer: Geographic Segmentation Analysis
 5.4 Autoimmune diseases
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Autoimmune diseases: Geographic Segmentation Analysis
 5.5 Infectious diseases
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Infectious diseases: Geographic Segmentation Analysis
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Geographic Segmentation Analysis

Chapter 6: Company Profiles and Competitive Analysis
 6.1 Competitive Landscape
  6.1.1 Competitive Benchmarking
  6.1.2 Immunotherapy Drugs Market Share by Manufacturer (2023)
  6.1.3 Industry BCG Matrix
  6.1.4 Heat Map Analysis
  6.1.5 Mergers and Acquisitions
  
 6.2 ABBVIE INC (UNITED STATES)
  6.2.1 Company Overview
  6.2.2 Key Executives
  6.2.3 Company Snapshot
  6.2.4 Role of the Company in the Market
  6.2.5 Sustainability and Social Responsibility
  6.2.6 Operating Business Segments
  6.2.7 Product Portfolio
  6.2.8 Business Performance
  6.2.9 Key Strategic Moves and Recent Developments
  6.2.10 SWOT Analysis
 6.3 AMGEN INC (UNITED STATES)
 6.4 ASTRAZENECA (UNITED KINGDOM)
 6.5 BAYER AG (GERMANY)
 6.6 BRISTOL-MYERS SQUIBB (UNITED STATES)
 6.7 ELI LILLY AND COMPANY (UNITED STATES)
 6.8 GILEAD SCIENCES (UNITED STATES)
 6.9 GLAXOSMITHKLINE (UNITED KINGDOM)
 6.10 JOHNSON & JOHNSON (UNITED STATES)
 6.11 MERCK & CO (UNITED STATES)
 6.12 NOVARTIS AG (SWITZERLAND)
 6.13 PFIZER INC (UNITED STATES)
 6.14 ROCHE HOLDING AG (SWITZERLAND)
 6.15 SANOFI (FRANCE)
 6.16 TAKEDA PHARMACEUTICAL COMPANY (JAPAN)
 6.17 OTHER

Chapter 7: Global Immunotherapy Drugs Market By Region
 7.1 Overview
 7.2. North America Immunotherapy Drugs Market
  7.2.1 Key Market Trends, Growth Factors and Opportunities
  7.2.2 Top Key Companies
  7.2.3 Historic and Forecasted Market Size by Segments
  7.2.4 Historic and Forecasted Market Size By Type
  7.2.4.1 Monoclonal antibodies
  7.2.4.2 Immunomodulators
  7.2.4.3 Vaccines
  7.2.5 Historic and Forecasted Market Size By Indication
  7.2.5.1 Cancer
  7.2.5.2 Autoimmune diseases
  7.2.5.3 Infectious diseases
  7.2.5.4 Others
  7.2.6 Historic and Forecast Market Size by Country
  7.2.6.1 US
  7.2.6.2 Canada
  7.2.6.3 Mexico
 7.3. Eastern Europe Immunotherapy Drugs Market
  7.3.1 Key Market Trends, Growth Factors and Opportunities
  7.3.2 Top Key Companies
  7.3.3 Historic and Forecasted Market Size by Segments
  7.3.4 Historic and Forecasted Market Size By Type
  7.3.4.1 Monoclonal antibodies
  7.3.4.2 Immunomodulators
  7.3.4.3 Vaccines
  7.3.5 Historic and Forecasted Market Size By Indication
  7.3.5.1 Cancer
  7.3.5.2 Autoimmune diseases
  7.3.5.3 Infectious diseases
  7.3.5.4 Others
  7.3.6 Historic and Forecast Market Size by Country
  7.3.6.1 Bulgaria
  7.3.6.2 The Czech Republic
  7.3.6.3 Hungary
  7.3.6.4 Poland
  7.3.6.5 Romania
  7.3.6.6 Rest of Eastern Europe
 7.4. Western Europe Immunotherapy Drugs Market
  7.4.1 Key Market Trends, Growth Factors and Opportunities
  7.4.2 Top Key Companies
  7.4.3 Historic and Forecasted Market Size by Segments
  7.4.4 Historic and Forecasted Market Size By Type
  7.4.4.1 Monoclonal antibodies
  7.4.4.2 Immunomodulators
  7.4.4.3 Vaccines
  7.4.5 Historic and Forecasted Market Size By Indication
  7.4.5.1 Cancer
  7.4.5.2 Autoimmune diseases
  7.4.5.3 Infectious diseases
  7.4.5.4 Others
  7.4.6 Historic and Forecast Market Size by Country
  7.4.6.1 Germany
  7.4.6.2 UK
  7.4.6.3 France
  7.4.6.4 Netherlands
  7.4.6.5 Italy
  7.4.6.6 Russia
  7.4.6.7 Spain
  7.4.6.8 Rest of Western Europe
 7.5. Asia Pacific Immunotherapy Drugs Market
  7.5.1 Key Market Trends, Growth Factors and Opportunities
  7.5.2 Top Key Companies
  7.5.3 Historic and Forecasted Market Size by Segments
  7.5.4 Historic and Forecasted Market Size By Type
  7.5.4.1 Monoclonal antibodies
  7.5.4.2 Immunomodulators
  7.5.4.3 Vaccines
  7.5.5 Historic and Forecasted Market Size By Indication
  7.5.5.1 Cancer
  7.5.5.2 Autoimmune diseases
  7.5.5.3 Infectious diseases
  7.5.5.4 Others
  7.5.6 Historic and Forecast Market Size by Country
  7.5.6.1 China
  7.5.6.2 India
  7.5.6.3 Japan
  7.5.6.4 South Korea
  7.5.6.5 Malaysia
  7.5.6.6 Thailand
  7.5.6.7 Vietnam
  7.5.6.8 The Philippines
  7.5.6.9 Australia
  7.5.6.10 New Zealand
  7.5.6.11 Rest of APAC
 7.6. Middle East & Africa Immunotherapy Drugs Market
  7.6.1 Key Market Trends, Growth Factors and Opportunities
  7.6.2 Top Key Companies
  7.6.3 Historic and Forecasted Market Size by Segments
  7.6.4 Historic and Forecasted Market Size By Type
  7.6.4.1 Monoclonal antibodies
  7.6.4.2 Immunomodulators
  7.6.4.3 Vaccines
  7.6.5 Historic and Forecasted Market Size By Indication
  7.6.5.1 Cancer
  7.6.5.2 Autoimmune diseases
  7.6.5.3 Infectious diseases
  7.6.5.4 Others
  7.6.6 Historic and Forecast Market Size by Country
  7.6.6.1 Turkey
  7.6.6.2 Bahrain
  7.6.6.3 Kuwait
  7.6.6.4 Saudi Arabia
  7.6.6.5 Qatar
  7.6.6.6 UAE
  7.6.6.7 Israel
  7.6.6.8 South Africa
 7.7. South America Immunotherapy Drugs Market
  7.7.1 Key Market Trends, Growth Factors and Opportunities
  7.7.2 Top Key Companies
  7.7.3 Historic and Forecasted Market Size by Segments
  7.7.4 Historic and Forecasted Market Size By Type
  7.7.4.1 Monoclonal antibodies
  7.7.4.2 Immunomodulators
  7.7.4.3 Vaccines
  7.7.5 Historic and Forecasted Market Size By Indication
  7.7.5.1 Cancer
  7.7.5.2 Autoimmune diseases
  7.7.5.3 Infectious diseases
  7.7.5.4 Others
  7.7.6 Historic and Forecast Market Size by Country
  7.7.6.1 Brazil
  7.7.6.2 Argentina
  7.7.6.3 Rest of SA

Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies

Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research